Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 1/20 | 0.59 |
| ▸ | CTSB | P07858 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 1/20 | 0.59 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944572 | 1.00 | HSD11B1 (0.65) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL3726979 | 1.00 | HSD11B1 (0.65) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL3313427 | 0.94 | USP30 (0.63) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL3313424 | 0.94 | USP30 (0.63) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL30165296 | 0.94 | USP30 (0.63) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL7870 | 0.93 | L3MBTL1 (0.58) | HSD11B1CTSLCTSBCTSKL3MBTL1 | |
| SCHEMBL13434239 | 0.93 | USP30 (0.59) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL21295099 | 0.93 | USP30 (0.59) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL18391123 | 0.92 | USP30 (0.58) | HSD11B1CTSLCTSBCTSKUSP30 | |
| SCHEMBL21064049 | 0.92 | USP30 (0.58) | HSD11B1CTSLCTSBCTSKUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113354635-B | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-113354635-A | Pyrrolidine integrin regulator and application thereof | 清药同创(北京)药物研发中心有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-106188027-B | Aromatic heterocyclic derivative and application thereof in medicine | 广东东阳光药业有限公司 | 2020-10-20 | — | — | CN | disclosed |
| EP-3071570-B1 | 2,6-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | PFIZER (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-104918615-A | Methods of treating liver diseases | ZAFGEN INC | 2015-09-16 | — | — | CN | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-2155719-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| EP-1546096-B1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| US-7064199-B2 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2006-06-20 | — | — | US | disclosed |
| EP-1546096-A1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | Basilea Pharmaceutica AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| US-6872836-B2 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2005-03-29 | — | — | US | disclosed |
| US-20040127703-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | MULLER MARC (FR) | 2004-07-01 | — | — | US | disclosed |
| US-20040034236-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | BASILEA PHARMACEUTICA AG (CH) | 2004-02-19 | — | — | US | disclosed |
| WO-2004013097-A1 | PROCESS FOR THE PREPARATION OF AMINO-PYRROLIDINE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2004-02-12 | — | — | WO | disclosed |
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | HSD11B1 375/4885CTSL 3305/4885CTSB 2326/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | HSD11B1 4093/4885CTSL 2634/4885CTSB 2044/4885 |
| US-20040127703-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | PRMT1, PEPD, PRMT3 | HSD11B1 1389/4885CTSL 721/4885CTSB 1895/4885 |
| US-20040034236-A1 | Process for the manufacture of 3-amino-pyrrolidine derivatives | PRMT1, PEPD, PRMT3 | HSD11B1 840/4885CTSL 1040/4885CTSB 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.